Know Your Ports - Oncology Nursing News
Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters such as Mediports.
How Nurses Help Patients With Prostate Cancer During Radiation …
Sep 23, 2024 · During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in Portland, Oregon, discussed some of radiation’s common adverse effects (AEs) for patients with prostate cancer, including irritable bowel symptoms; urinary urgency, frequency, and burning; erectile dysfunction; ejaculatory change; and fatigue.
Onvansertib Combo Appears Efficacious in KRAS+ Metastatic …
Dec 3, 2024 · The addition of onvansertib to folinic acid, fluorouracil, and irinotecan hydrochloride (FOLFIRI) and bevacizumab (Avastin) demonstrated efficacious clinical activity among patients with KRAS-mutated metastatic colorectal cancer (CRC) in the second-line setting, according to findings from a multicenter, open-label, single-arm phase 2 trial (NCT06106308) published in …
Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant …
Feb 17, 2023 · Tamoxifen, at a dose of 5 mg daily (babytam), continued to show a benefit over placebo in reducing the risk of recurrence from invasive breast cancers and ductal carcinoma in situ (DCIS) in women with breast intraepithelial neoplasia in a 10-year follow-up of the TAM-01 trial (NCT01357772).
Hypofractionated Radiation Noninferior for Lymphedema …
Sep 16, 2024 · Moderately hypofractionated, locoregional radiation was not inferior to normofractionated radiation therapy in reducing lymphedema risk in patients with early-stage breast cancer, according to data from the phase 3 HypoG-01 trial (NCT03127995).
FDA Approves First and Only Systemic Therapy for NRG1+ Lung, …
Dec 4, 2024 · The FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri) as the first systemic therapy for patients with non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (PDAC) harboring an NRG1 gene fusion. 1
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent ...
Apr 1, 2022 · PD-L1 combined positive score (CPS) may serve to predict whether a patient with PD-L1–expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) will receive optimal benefit with pembrolizumab (Keytruda) alone vs in combination with chemotherapy or with cetuximab (Erbitux) plus chemotherapy, according to an efficacy …
20 Inspirational Quotes for Cancer Survivors, Fighters, and Caregivers
Aug 25, 2015 · The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast …
Oct 24, 2024 · The American Society of Clinical Oncology (ASCO) recently announced guidelines outlining a preference for abemaciclib (Verzenio) over ribociclib (Kisqali) for the treatment of patients with node-positive, high-risk, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 1. The recommendation is based on findings from …
Tislelizumab Plus Chemotherapy Receives FDA Approval for First …
Dec 27, 2024 · The FDA has approved tislelizumab-jsgr (Tevimbra) for use with platinum- and fluoropyrimidine-based chemotherapy in the first-line setting for unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). 1,2 The regulatory decision was supported by data from the phase 3 …